Cargando…
Thrombolytic Agents: Nanocarriers in Targeted Release
A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.)...
Autores principales: | Shen, Minghua, Wang, Yujiao, Hu, Fan, Lv, Linwen, Chen, Kui, Xing, Gengmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619279/ https://www.ncbi.nlm.nih.gov/pubmed/34833868 http://dx.doi.org/10.3390/molecules26226776 |
Ejemplares similares
-
Thrombus-Targeting Polymeric Nanocarriers and Their Biomedical Applications in Thrombolytic Therapy
por: Guan, Qixiao, et al.
Publicado: (2021) -
The High Permeability of Nanocarriers Crossing the Enterocyte Layer by Regulation of the Surface Zonal Pattern
por: Chang, Ya-Nan, et al.
Publicado: (2020) -
Thrombolysis: Biological and Therapeutic Properties of New Thrombolytic Agents
por: Chen, Fabian
Publicado: (1987) -
Recent strategies on targeted delivery of thrombolytics
por: Huang, Ting, et al.
Publicado: (2019) -
Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?
por: Mahmood, Ammad, et al.
Publicado: (2022)